Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/american-medical-association/vaccines-as-an-integral-component-of-cancer-immunotherapy-fP0GIuwHi0
References (10)
-
R. Marconcini, F. Spagnolo, L. Stucci, S. Ribero, E. Marra, F. Rosa, V. Picasso, L. Guardo, C. Cimminiello, S. Cavalieri, L. Orgiano, E. Tanda, L. Spano, A. Falcone, P. Queirolo (2015)
Current status and perspectives in immunotherapy for metastatic melanomaOncotarget, 9
-
Chi Wong, K. Siah, A. Lo (2018)
Estimation of clinical trial success rates and related parametersBiostatistics (Oxford, England), 20
-
C. Heery, B. Singh, M. Rauckhorst, J. Marté, R. Donahue, I. Grenga, T. Rodell, W. Dahut, P. Arlen, R. Madan, J. Schlom, J. Gulley (2015)
Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor BrachyuryCancer Immunology Research, 3
-
Benjamin Boyerinas, C. Jochems, M. Fantini, C. Heery, J. Gulley, K. Tsang, J. Schlom (2015)
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor CellsCancer Immunology Research, 3
-
Yoshiko Iwai, J. Hamanishi, K. Chamoto, T. Honjo (2017)
Cancer immunotherapies targeting the PD-1 signaling pathwayJournal of Biomedical Science, 24
-
R. Andtbacka, H. Kaufman, F. Collichio, T. Amatruda, N. Senzer, J. Chesney, K. Delman, L. Spitler, I. Puzanov, S. Agarwala, M. Milhem, L. Cranmer, B. Curti, K. Lewis, M. Ross, T. Guthrie, G. Linette, G. Daniels, K. Harrington, M. Middleton, W. Miller, J. Zager, Y. Ye, B. Yao, Ai Li, S. Doleman, A. Vanderwalde, J. Gansert, R. Coffin (2015)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 25
-
J. Strauss, C. Heery, J. Schlom, R. Madan, Liang Cao, Zhigang Kang, E. Lamping, J. Marté, R. Donahue, I. Grenga, L. Cordes, O. Christensen, L. Mahnke, C. Helwig, J. Gulley (2018)
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid TumorsClinical Cancer Research, 24
-
H. Rajabi, D. Kufe (2017)
MUC1-C Oncoprotein Integrates a Program of EMT, Epigenetic Reprogramming and Immune Evasion in Human Carcinomas.Biochimica et biophysica acta. Reviews on cancer, 1868 1
-
L. Pathangey, Dustin McCurry, S. Gendler, A. Dominguez, Jessica Gorman, Girish Pathangey, Laurie Mihalik, Y. Dang, M. Disis, P. Cohen (2016)
Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigensOncotarget, 8
-
E. Small, P. Schellhammer, C. Higano, C. Redfern, J. Nemunaitis, F. Valone, S. Verjee, L. Jones, R. Hershberg (2006)
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 19
- Publisher
- American Medical Association
- Copyright
- Copyright 2018 American Medical Association. All Rights Reserved.
- ISSN
- 0098-7484
- eISSN
- 1538-3598
- DOI
- 10.1001/jama.2018.9511
- Publisher site
- See Article on Publisher Site
Abstract
This Viewpoint reviews recent preclinical developments in the use of therapeutic cancer vaccines to induce immune responses to tumor-associated antigens, alone or in combination with other therapies, such as tumor checkpoint inhibitor monoclonal antibodies, to render resistant (cold) tumor cells susceptible to T-cell antitumor activity.
Journal
JAMA – American Medical Association
Published: Dec 4, 2018